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The goal of almost all anticancer treatments is to kill cancercells. Nevertheless, although death may seem like a sim-
ple period at the end of every cell’s life, the final processes
leading to the extinction of any given cell are both complex
and varied.
Apoptosis is one of several different mechanisms of
cell death. It is characterized by the activation of a series of
intracellular proteinases, called caspases, which ultimately
cleave proteins essential for cell survival. Two broad routes,
the intrinsic and extrinsic apoptotic pathways, lead to irrevo-
cable caspase activation, converging into a common terminal
pathway in the final stages of apoptotic cell death. The
intrinsic pathway relies on incompletely understood cellular
damage recognition mechanisms that trigger the release of
cytochrome C from the mitochondria to start a caspase
activation cascade. In contrast, the extrinsic pathway relies on
the stimulation of any of a series of cell surface death
receptors, such as the tumor necrosis factor (TNF) receptor or
the TNF-related apoptosis inducing ligand (TRAIL) receptors
to generate an initial caspase activation cascade.1
Each activation step is carefully balanced by a series of
inactivation or inhibitory steps. Consequently, it is only in the
presence of overwhelming prodeath signaling that sufficient
momentum can be built up to tip cells into terminal caspase
activation. Recognized brakes on proapoptotic signaling,
working at different points in the apoptotic cascade, include
the inhibitor of apoptosis proteins (IAPs) such as cIAP1,
cIAP2, and XIAP and their more distantly related cousin
survivin and the antiapoptotic BCL2 family of proteins such
as BCL2 and BCL-XL.
Many of the abnormalities present within cancer cells,
and the microenvironmental effects associated with uncon-
trolled growth should generate, under other circumstances,
significant proapoptotic drive. Therefore, for cancer cells to
persist, this natural self-regulation must have been subverted.
Indeed, avoidance of apoptosis is now well recognized as one
of the hallmarks of cancer.2 This does not simply mean that
it is always more difficult to induce apoptosis in cancer cells
than their normal counterparts. Rather, the situation is con-
siderably more complicated and these complications provide,
at least in theory, a way to selectively and effectively kill
tumor cells. In some situations, cancer cells may have such a
loose grip on survival that interference with one specific
antiapoptotic mechanism alone could be sufficient to kill the
cell. Alternatively, the down-regulation of proapoptotic sig-
naling may have knock-on effects making the cancer cells
harder to kill when using traditional chemo- or radiothera-
peutic techniques, but only if these therapies ultimately act
through aspects of the same apoptotic pathway. Following
either or both rationales, several different pharmacological
attempts to directly manipulate either the intrinsic or extrinsic
apoptotic pathway have been, or continue to be, explored in
the treatment of lung cancer.
Summary of Presentations
SMAC Mimetics (IAP Inhibitors)
The IAP family of proteins inhibit aspects of the
caspase activation cascade associated with the extrinsic, in-
trinsic, and common apoptotic pathways.3 The activity of the
IAPs is regulated by a number of natural antagonists includ-
ing second mitochondria-derived activator of caspases
(SMAC) that binds at the BIR domains of the IAPs (notably
XIAP, cIAP1, and cIAP2), limiting their interaction with
caspases and targeting them for degradation. Through ad-
vances in peptidomimetic chemistry, small-molecule SMAC
mimetics have been developed with the potential to function
as pharmacological IAP inhibitors.3 The valency of SMAC
mimetics influences both their binding affinity and spectrum
of activity against the IAPs. Preclinical monotherapy studies
of SMAC mimetics reveal significant variations in sensitivity
across different cancer cell lines with the most sensitive lines
(approximately 15% of NSCLC lines) being characterized by
high intrinsic levels of TNF-receptor signaling via autocrine
TNF-alpha secretion.4 In contrast, synergistic interactions
between SMAC mimetics and TRAIL-receptor agonists or
cytotoxic chemotherapies can occur independent of TNF
signaling.5 Nevertheless, the degree of IC50 decrease seen
with a SMAC mimetic combination varies by both the
NSCLC cell line used and the specific cytotoxic agent used.
At least four different SMAC mimetics are currently in early
phase clinical trials in either hematological or general solid
tumor populations, exploring both monotherapy and cyto-
toxic combination approaches.
Survivin Inhibitors
Survivin is a member of the IAP family but also has a
role as a cell cycle regulator. It is commonly overexpressed in
many different cancers. YM155, identified using a high
throughput survivin promoter luciferase assay, inhibits the
transcription of survivin. YM155 is administered intrave-
nously from day 1 to 7 in a 21-day cycle.6 Clinical data are
limited, but within the phase I study, partial responses were
seen in NHL, PSA responses in prostate cancer, and a minor
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response in NSCLC. YM155 is being explored in phase II
monotherapy studies in melanoma, prostate cancer (do-
cetaxel), and NHL. LY2181308 is a survivin antisense mol-
ecule that has had a relatively slow development path to date.
It has demonstrated pharmacodyamic down-regulation of
survivin in patients within the phase I study7 but without
evidence of significant tumor shrinkage. Monotherapy and
combination studies, including chemotherapy combination
studies in NSCLC have been undertaken.
BCL2 Inhibitors
The BCL2 gene is amplified in approximately 40% of
SCLC. BAD is a naturally occurring antagonist of BCL2, and
potent BCL2 family inhibitors have been generated using
peptidomimetic chemistry to generate a series of BAD mi-
metics. ABT-737 is a preclinical probe compound directed
against BCL2 and BCL-XL that has shown monotherapy
activity in a number of different SCLC models.8 ABT-263 is
an orally bioavailable derivative of ABT-737 that has been
explored clinically. Use of ABT-263 has demonstrated new
insights into platelet physiology with older platelets appear-
ing to use BCL-XL to hold off senescence. Consequently,
rapid drops in platelet counts with ABT-263 reflect the
depopulation of older platelets rather than classical myelo-
suppression and can be abrogated through gradual intrapa-
tient dose escalation.9 Unfortunately, monotherapy activity
seems limited with only a single objective response seen out
of 26 SCLC patients.9 Combination studies with platinum and
etoposide in advanced SCLC are ongoing.
TRAIL-receptor Agonists
Both recombinant human TRAIL (Apo2L) and agonis-
tic monoclonal antibodes directed against either TRAIL-
Receptor 1 or 2 (also known as Death Receptors 4 and 5,
respectively) have all recently been tried in combination with
standard first-line platinum doublets (with and without bev-
acizumab) in advanced NSCLC. Despite hints of mono-
therapy activity in subsets of NSCLC cell lines and in isolated
lung cancer patients in all-comer phase I studies, in all cases
the randomized phase II combination studies failed to dem-
onstrate improvements in either response rate or progression-
free survival.10–13 Further development of most of these
agents in NSCLC seems to have been discontinued.
Future Directions
Are we missing something?
Although cell death seems straightforward, it is not.
Nor is it implemented in the same way between different
cancers and in response to seemingly similar “cytotoxic”
therapies. Preclinical monotherapy activity of IAP inhibitors
seems restricted to cell lines with significant autocrine TNF
signaling.4 Only 1 of 26 patients with SCLC manifested a
significant response to ABT-263 monotherapy and only one
of seven patients with NSCLC manifested a significant mono-
therapy response to conatumumab (a TRAIL-receptor 2/death
receptor 5 agonist) with no other NSCLC signal identified in
any of the other TRAIL receptor agonist all-comers phase I
studies.9,10 Why should we expect monotherapy activity only
seen in selected preclinical models to translate into significant
clinical activity in unselected lung cancer populations? Al-
though combination studies of apoptotic manipulators with
chemotherapy offer the promise of broader activity, again
preclinical data reveal the heterogeneity between different
cancer models in the degree of synergism observed and the
previously unsuspected potential for different cytotoxics to
drive death in different ways. All the negative platinum
chemotherapy combination studies with the TRAIL agonists
were conducted in general NSCLC populations but, intrigu-
ingly, in several of these studies, a significant tail of nonpro-
gressors in the experimental arm, accounting for up to 15% of
the treated population, is apparent in the PFS curves.11,12
Unfortunately, more negative studies with apoptotic manip-
ulators in unselected populations may well be on the way, but
before we lose faith in these agents, we should rethink the
idea of death being a uniform phenomenon. It is time to
embrace the clinical search for molecular subgroups that are
supersensitive to these agents, just as much as we have
already started to do for tyrosine kinase inhibitors in the
oncology population.
REFERENCES
1. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis
in cancer treatment. Lancet Oncol 2008;9:1002–1011.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
Cell 2011;144:646–674.
3. Mannhold R, Fulda S, Carosati E. IAP antagonists: promising candidates
for cancer therapy. Drug Discov Today 2010;15:210–219.
4. Wu H, Tschopp J, Lin SC. Smac mimetics and TNFalpha: a dangerous
liaison? Cell 2007;131:655–658.
5. Varfolomeev E, Alicke B, Elliott JM, et al. X chromosome-linked
inhibitor of apoptosis regulates cell death induction by proapoptotic
receptor agonists. J Biol Chem 2009;284:34553–34560.
6. Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic
study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol
2008;26:5198–5203.
7. Talbot DC, Ranson M, Davies J, et al. Tumor survivin is downregulated
by the antisense oligonucleotide LY2181308: a proof-of-concept, first-
in-human dose study. Clin Cancer Res 2010;16:6150–6158.
8. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737,
a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res
2008;68:2321–2328.
9. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of
Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with
small-cell lung cancer and other solid tumors. J Clin Oncol 2011;29:
909–916.
10. Herbst RS, Kurzrock R, Hong DS, et al. A first-in-human study of
conatumumab in adult patients with advanced solid tumors. Clin Cancer
Res 2010;16:5883–5891.
11. Blackhall FH, Ma´rk Z, Zatloukal P, et al. A randomized phase II study
of paclitaxel and carboplatin bevacizumab dulanermin in non-small
cell lung cancer. J Clin Oncol 2010;28:15s (Suppl; abstract 7534).
12. Von Pawel J, Harvey JH, Spigel DR, et al. A randomized phase II trial
of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in com-
bination with carboplatin and paclitaxel in patients with advanced
NSCLC. J Clin Oncol 2010;28:18s (Suppl; abstract LBA7501).
13. Karapetis CS, Clingan PR, Leighl NB, et al. Phase II study of PRO95780
plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell
lung cancer. J Clin Oncol 2010;28:15s (Suppl; abstract 7535).
Journal of Thoracic Oncology • Volume 6, Number 11, Supplement 4, November 2011 Santa Monica Supplement
Copyright © 2011 by the International Association for the Study of Lung Cancer S1819
